Info Sheet

IBC Review and Consulting Services

September 30, 2019

No more waiting for a standing meeting. No submission deadlines. Responsive and flexible—only 10 business days or less from submission to institutional biosafety committee (IBC) review.

Blog

How Centralized IBC Review Can Benefit Gene Therapy Research

September 18, 2019

Gene therapy research is at the forefront of a coming boom in the clinical setting. Understand the growth, risks, and regulatory requirements here.

Webinar

Preparing for Multisite Gene Therapy Studies

The fast and dramatic growth in the field of gene therapy is unprecedented, as the US FDA and regulatory agencies of several other countries have begun issuing approvals for licensed…

Info Sheet

IBC-Ready™ Support

December 13, 2018

With IBC-Ready™, Advarra can help reduce confusion and administrative burden by coordinating with the sponsor, site personnel and local IBC(s) to complete local IBC submission forms.

Blog

Infection Control and Biosafety in Gene Therapy Research

October 29, 2018

Gene therapy research has moved from the realm of science fiction to mainstream clinical research. The maturation of this field...

Blog

Integration Update: Leading Compliance Adherence

October 15, 2018

The Advarra team is proud to announce that all major integration activities are now complete. SOPs have been harmonized; staff...

Webinar

An Introduction to Human Gene Transfer Research and Institutional Biosafety Committees (IBCs)

July 19, 2018

Advarra’s Director of Biosafety Services Daniel Eisenman discusses the basics of research involving genetic engineering and the role played by the IBC in conducting safe and responsible research.

Blog

Integration Update: Recent Milestones Completed

May 23, 2018

The Advarra team has worked to fully integrate our processes and policies to provide clients with unified capabilities and support...

Info Sheet

Advarra Services Overview

April 25, 2018

Advarra's integrated research compliance solutions help make your research altogether better.